publication venue for
- T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. 2022
- Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.. 18. 2021
- KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.. 17. 2021
- Prognostic implications of depression and inflammation in patients with metastatic lung cancer.. 17. 2020
- Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.. 17. 2020
- First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.. 17. 2020
- Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.. 16. 2020
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.. 15. 2019
- Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.. 15. 2019
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.. 13. 2016
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.. 12. 2016
- A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.. 12. 2015
- Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.. 7. 2011
- The role of external beam in brachytherapy.. 3. 2007
- Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? 2022
- A global approach to inflammatory breast cancer. 2011
- A promising cancer vaccine.. 7. 2011
- Nanomolecular targeting of dendritic cells for ovarian cancer therapy.. 5. 2009
- Tumor microenvironment of metastasis (TMEM): a novel tissue-based assay for metastatic risk in breast cancer.. 5. 2009
- Talking to patients about biosimilars. 2018
- Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. 2018
- A critical review on ramucirumab in the treatment of advanced urothelial cancer. 2017
- Imaging of local recurrence in prostate cancer. 2016
- Nodal metastases in thyroid cancer: prognostic implications and management. 2016
- Current advances in targeted therapies for metastatic gastric cancer: improving patient care. 2016
- Novel approaches to imaging basal cell carcinoma. 2015
- Role of MRI in the diagnosis and management of prostate cancer. 2015
- Emerging applications of stereotactic body radiotherapy. 2014
- Tissue engineering and regeneration of lymphatic structures. 2013
- Advances in sentinel lymph node mapping for patients with melanoma. 2012
- Stereotactic body radiation therapy for prostate cancer. 2011
- Imaging assessment of tumor response: past, present and future. 2011
- High-risk prostate cancer: the role of radical prostatectomy for local therapy. 2011
- Predictive markers of colorectal cancer liver metastases. 2011
- Fatty acid synthase as a potential therapeutic target in cancer. 2010
- Effect of the number of biopsy cores on prostate cancer detection and staging. 2010
- Critical review of prostate cancer predictive tools. 2009
- Roles of LPA in ovarian cancer development and progression. 2009
- Clinical states model for biomarkers in bladder cancer. 2009
- Diffusion-weighted imaging in head and neck cancers. 2009
- Prostate cancer: psychosocial implications and management. 2008
- Current and future surgical approaches in the management of endometrial carcinoma. 2008
- Percutaneous renal cryoablation: current status. 2008
- Blood biomarkers for prostate cancer detection and prognosis. 2007
- Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary. 2023
- Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors. 2023
- Plain Language Summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? 2023
- Single versus multiple session stereotactic body radiotherapy for spinal metastasis: the risk-benefit ratio. 2015
- Dose-dense chemotherapy for breast cancer: what does the future hold? 2010
- Satraplatin for the therapy of castration-resistant prostate cancer. 2009
- Cetuximab in squamous cell carcinoma of the head and neck. 2006
- The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. 2006